Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q3 FY25 results · Oct–Dec 2024
Marksans Pharma reported revenue from operations of ₹681.85 crore (up 16.3% from Q3 FY24) and net profit of ₹105.07 crore (up 26.6% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 681.85 | 586.13 | +16.3% | 641.92 | +6.2% |
| Other income | 27.85 | 4.80 | +480.2% | 11.06 | +151.8% |
| Total income | 709.70 | 590.93 | +20.1% | 652.98 | +8.7% |
| Profit before tax | 143.26 | 112.66 | +27.2% | 124.60 | +15.0% |
| Net profit for the period | 105.07 | 82.97 | +26.6% | 97.76 | +7.5% |
| Attributable to shareholders of the company | 104.56 | 83.23 | +25.6% | 96.72 | +8.1% |
| EPS, basic (₹) | 2.31 | 1.84 | +25.4% | 2.13 | +8.3% |
| Net margin (%) | 15.4 | 14.2 | 15.2 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 311.87 | 241.36 | +29.2% | 308.62 | +1.0% |
| Other income | 22.51 | 1.32 | 17x | 31.36 | −28.2% |
| Total income | 334.37 | 242.69 | +37.8% | 339.98 | −1.6% |
| Profit before tax | 74.72 | 34.60 | +116.0% | 76.34 | −2.1% |
| Net profit for the period | 55.46 | 25.29 | +119.3% | 63.20 | −12.2% |
| EPS, basic (₹) | 1.22 | 0.56 | +117.9% | 1.39 | −12.2% |
| Net margin (%) | 17.8 | 10.5 | 20.5 |
Consolidated
- Filed with BSE
- 11 Feb 2025, 22:10 IST
- Board meeting
- 11 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Feb 2025, 22:10 IST
- Board meeting
- 11 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE